Back

Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: A post-hoc analysis from the REWIND randomized trial

21 May 2022 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Heart Failure ePosters - focus on Chronic Heart Failure 3 Comorbidities HFA Premium Access Heart Failure 2022

About the speaker

Photo
Professor Kelley Branch

University of Washington, Seattle (United States of America)

35 More presentations in this session

Presentation thumbnail
Prognostic value of pulse pressure in heart failure with preserved ejection fraction: findings from the RICA registry
Doctor I. Bravo Candela (Sevilla, ES)
Abstract Slides
Presentation thumbnail
Repetitive ambulatory doses of levosimendan for patients as bridge to heart transplant. Findings from the LEVO-T registry.
Doctor J. De Juan Baguda (Madrid, ES)
Abstract Slides
Presentation thumbnail
Sacubitril/valsartan use patterns among older adults with heart failure in routine care: a US population-based cohort study of >25,000 medicare beneficiaries
Doctor A. Bhatt (Boston, US)
Abstract Slides
Presentation thumbnail
Efficacy of sodium glucose cotransporter-2 inhibitors for heart failure with preserved and with mildly reduced ejection fraction: a systematic review and meta-analysis
Doctor R. Cordovez (Cebu City, PH)
Abstract Slides
Presentation thumbnail
Prognostic value of late diastolic strain rate in patients with heart failure with reduced ejection fraction
Doctor O. Nemchyna (Berlin, DE)
Abstract Slides

Access the full session

Session thumbnail
Heart Failure ePosters - focus on Chronic Heart Failure 3

The Event

Event poster

Heart Failure 2022

21 May - 24 May 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources